Hera News & Events


Fine Needle Aspirate Serial Tumor Sampling Services to Boost Your Xenograft Study Capabilities

Xenograft tumors from human cancer cell lines in immunocompromised mice are [...]

Validation of the SRG Rat for Human Tumor Studies Published in PLOS ONE

We are excited to announce that a validation study using [...]

Gene Editing With piggyBac: Creating A Curative Treatment For Beta-Thalassemia

Genetic engineering can soon lead to lifelong cures for diseases [...]

OncoRat® featured in Clinical Cancer Research for prostate cancer studies

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems: A case [...]

The OncoRat® is the ideal host for patient-derived xenografts of ovarian cancer cells

Ovarian cancer is the most lethal gynecological cancer in the [...]

Evolution of the rat model

Rats have been favored for drug development studies because the [...]

H358 NSCLC xenografts in humanized rats: the ideal in vivo model for studying KRAS mutations

Lung adenocarcinomas, the major histological subtype of non-small cell lung [...]

Hera Biolabs announces Molecular Cancer Therapeutics publication on immunodeficient rats for oncology research

Hera Biolabs, the University of Michigan, Case Western Reverse University and other collaborators are announcing a recent publication in the American Association for Cancer Research (AACR) journal, Molecular Cancer Therapeutics, entitled, "Sprague Dawley Rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts."

Breakthroughs in gene editing allow for the creation of superior preclinical oncology models

Gene editing is getting a lot of attention in the [...]

The OncoRat®: Hosting valuable tumor xenograft models that are difficult or impossible to study using in vitro or mouse models

One of the most widely used methods of modeling human [...]